Guatemala vs Kazakhstan: Average cost of drugs for extensively drug-resistant tuberculosis
Guatemala
11,910 constant 2022 US$
in 2024
Kazakhstan
6,329 constant 2022 US$
in 2023
Guatemala rank
3rd
Kazakhstan rank
5th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guatemala
- Kazakhstan
How they compare
Guatemala currently reports 11,910 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan, a difference of 5,581 constant 2022 US$.
That makes Guatemala's figure about 1.9 times Kazakhstan's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Guatemala ahead.
Guatemala ranks 3rd and Kazakhstan ranks 5th of 56 countries.
Across the 2 decades both report, Guatemala averaged higher in 1 and Kazakhstan in 1.
Head to head by decade
| Decade | Guatemala | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 11,075 constant 2022 US$ | 4,366 constant 2022 US$ | 6,708 constant 2022 US$ | Guatemala |
| 2020s | 4,509 constant 2022 US$ | 4,806 constant 2022 US$ | 296.5 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guatemala or Kazakhstan?
- Guatemala, at 11,910 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guatemala and Kazakhstan?
- 5,581 constant 2022 US$, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and Kazakhstan?
- 6 years are reported by both, from 2017 to 2023.
- How do Guatemala and Kazakhstan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guatemala ranks 3rd and Kazakhstan ranks 5th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.